Genmab pipeline hype makes investment bank uneasy
The expectations for Genmab's pipeline are too high, says Germany-based investment bank Berenberg Bank, which has changed its share recommendation as it cannot justify the current pricing.
by marketwire, translated by catherine brett
Although Genmab has been called a "superstar" and "one of the best European biotech companies," Berenberg Bank has changed its recommendation to "sell", with a target price of DKK 2,200 (USD 334).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Anthony Mancini will help Genmab take its next steps
For subscribers
